Protagonist Therapeutics, Inc Quarterly Net Income (Loss) Attributable to Parent in USD from Q1 2015 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Protagonist Therapeutics, Inc quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q1 2015 to Q2 2024.
  • Protagonist Therapeutics, Inc Net Income (Loss) Attributable to Parent for the quarter ending June 30, 2024 was -$30.6M, a 20.4% increase year-over-year.
  • Protagonist Therapeutics, Inc Net Income (Loss) Attributable to Parent for the twelve months ending June 30, 2024 was $170M.
  • Protagonist Therapeutics, Inc annual Net Income (Loss) Attributable to Parent for 2023 was -$79M, a 38% increase from 2022.
  • Protagonist Therapeutics, Inc annual Net Income (Loss) Attributable to Parent for 2022 was -$127M, a 1.47% decline from 2021.
  • Protagonist Therapeutics, Inc annual Net Income (Loss) Attributable to Parent for 2021 was -$126M, a 89.8% decline from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 $170M -$30.6M +$7.84M +20.4% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-06
Q1 2024 $162M $207M +$241M Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-07
Q4 2023 -$79M $27.3M +$61.5M Oct 1, 2023 Dec 31, 2023 10-K 2024-02-27
Q3 2023 -$140M -$34.1M -$2.87M -9.2% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-02
Q2 2023 -$138M -$38.5M +$2.58M +6.28% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-06
Q1 2023 -$140M -$33.7M -$12.8M -61.1% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-07
Q4 2022 -$127M -$34.2M +$2.71M +7.35% Oct 1, 2022 Dec 31, 2022 10-K 2024-02-27
Q3 2022 -$130M -$31.2M +$2.57M +7.61% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-02
Q2 2022 -$133M -$41M -$10.2M -33.1% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-03
Q1 2022 -$122M -$20.9M +$3.07M +12.8% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-04
Q4 2021 -$126M -$36.9M -$18M -95.4% Oct 1, 2021 Dec 31, 2021 10-K 2024-02-27
Q3 2021 -$108M -$33.8M -$26M -335% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-08
Q2 2021 -$81.5M -$30.8M -$11.4M -58.8% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-04
Q1 2021 -$70.1M -$24M -$3.92M -19.5% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-05
Q4 2020 -$66.2M -$18.9M -$1.39M -7.91% Oct 1, 2020 Dec 31, 2020 10-K 2023-03-15
Q3 2020 -$64.8M -$7.76M +$8.65M +52.7% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-03
Q2 2020 -$73.4M -$19.4M +$9.75M +33.4% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-04
Q1 2020 -$83.2M -$20.1M -$5.98M -42.4% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-04
Q4 2019 -$77.2M -$17.5M -$3.64M -26.2% Oct 1, 2019 Dec 31, 2019 10-K 2020-03-10
Q3 2019 -$73.6M -$16.4M -$7.67M -87.9% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-04
Q2 2019 -$65.9M -$29.2M -$20.5M -237% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-06
Q1 2019 -$45.4M -$14.1M -$6.44M -84.1% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-07
Q4 2018 -$38.9M -$13.9M -$10.8M -354% Oct 1, 2018 Dec 31, 2018 10-K 2020-03-10
Q3 2018 -$28.1M -$8.74M -$3.91M -81% Jul 1, 2018 Sep 30, 2018 10-K 2020-03-10
Q2 2018 -$24.2M -$8.66M +$6.32M +42.2% Apr 1, 2018 Jun 30, 2018 10-K 2020-03-10
Q1 2018 -$30.5M -$7.66M +$6.44M +45.7% Jan 1, 2018 Mar 31, 2018 10-K 2020-03-10
Q4 2017 -$37M -$3.05M +$8.2M +72.9% Oct 1, 2017 Dec 31, 2017 10-K 2019-03-12
Q3 2017 -$45.2M -$4.83M +$2.26M +31.9% Jul 1, 2017 Sep 30, 2017 10-K 2019-03-12
Q2 2017 -$47.4M -$15M -$7.88M -111% Apr 1, 2017 Jun 30, 2017 10-K 2019-03-12
Q1 2017 -$39.5M -$14.1M -$2.35M -20% Jan 1, 2017 Mar 31, 2017 10-K 2019-03-12
Q4 2016 -$37.2M -$11.2M -$5.76M -105% Oct 1, 2016 Dec 31, 2016 10-K 2018-03-07
Q3 2016 -$31.4M -$7.08M -$3.64M -105% Jul 1, 2016 Sep 30, 2016 10-K 2018-03-07
Q2 2016 -$27.8M -$7.1M -$3.88M -121% Apr 1, 2016 Jun 30, 2016 10-K 2018-03-07
Q1 2016 -$23.9M -$11.7M -$9.05M -336% Jan 1, 2016 Mar 31, 2016 10-K 2018-03-07
Q4 2015 -$14.9M -$5.49M Oct 1, 2015 Dec 31, 2015 10-K 2017-03-07
Q3 2015 -$3.45M Jul 1, 2015 Sep 30, 2015 10-K 2017-03-07
Q2 2015 -$3.22M Apr 1, 2015 Jun 30, 2015 10-K 2017-03-07
Q1 2015 -$2.7M Jan 1, 2015 Mar 31, 2015 10-K 2017-03-07
* An asterisk sign (*) next to the value indicates that the value is likely invalid.